Founded in 1950, Denka Seiken (now part of Denka) has long focused on the development of diagnostic reagents and vaccines, supporting clinical laboratories and public health testing with immunoassays, clinical chemistry reagents, microbiology products, and rapid tests. Denka also develops key in-house technologies (e.g., monoclonal antibody development) used across its diagnostic reagent portfolio.

■ Product Portfolio

Vicbio Biotechnology Co., Ltd. provides the full range of Denka Seiken products.

⇨ Inquire or Order immediately ⇦

•Immunochemistry: Diagnostic reagents based on antigen–antibody reactions for accurate measurement of serum proteins in blood. Main formats include:Latex agglutination reagents (latex particle agglutination-based detection) and TIA reagents (turbidimetric immunoassay measuring aggregates formed by antigen–antibody reactions). Both are designed to run on general-purpose automated analyzers for fast, convenient testing.

•Clinical Chemistry: Reagents used not only for disease diagnosis but also for screening and prevention programs. Compatible with general-purpose automated analyzers, enabling rapid routine testing—especially for direct HDL-C and LDL-C measurement.

•Bacteriology: Denka’s bacterial typing antisera are widely used in clinical microbiology and public health laboratories in Japan. The portfolio supports broad bacterial serotyping and includes toxin-related assays such as E. coli Shiga toxin and Staphylococcal enterotoxin detection reagents.

•Virology: Leveraging proprietary platforms (cell/virus culture, cell fusion, recombinant DNA, etc.), Denka develops antigen/antibody tests for viral infection diagnosis using serum, plasma, stool, and other body fluids.

•Advanced Cardiovascular Risk Biomarkers: Assay menu covering biomarkers such as LDL-C, Lp(a), small dense LDL-C, CRP, HDL-C, remnant lipoprotein cholesterol, and more.

•POCT (Point-of-Care Testing): Denka develops and supplies the QuickNavi™ series of rapid diagnostic kits for infectious disease antigen detection.

■ Featured Product (In Stock): Denka Seiken Receptor Destroying Enzyme Ⅱ — RDE (II) “SEIKEN” (Cat. 340122)

RDE (II) “SEIKEN” is used for influenza virus HI (hemagglutination inhibition) testing to eliminate non-specific hemagglutination inhibitors in serum specimens. It uses receptor destroying enzyme produced from Vibrio cholerae serovar Ogawa strain 558. The product is supplied as a lyophilized preparation, 20 mL × 5 vials, and each vial contains 2 mg kanamycin sulfate as a preservative.